Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus TELMISARTAN HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus TELMISARTAN HYDROCHLOROTHIAZIDE.
FILSPARI vs TELMISARTAN; HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Telmisartan is an angiotensin II receptor antagonist that selectively blocks the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption.
200 mg orally once daily, with or without food.
Initial dose: 40 mg telmisartan/12.5 mg hydrochlorothiazide orally once daily. Titrate up to 80 mg telmisartan/25 mg hydrochlorothiazide once daily as tolerated.
None Documented
None Documented
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Telmisartan: ~24 hours (range 18–24 h), enabling once-daily dosing. Hydrochlorothiazide: 6–15 hours (average ~9 h); prolonged in renal impairment.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Telmisartan: predominantly biliary/fecal (≥97%), renal <1%. Hydrochlorothiazide: predominantly renal (≥95%) as unchanged drug.
Category C
Category D/X
Endothelin Receptor Antagonist / ARB
ARB